Celyad Oncology S.A.
CYAD
Classificação em ações
#31515
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Preço da ação
$0.25267839
Última sincronização: 2026-10-21
Valor de mercado
$11.94M
Variação (1 dia)
1.44%
Variação (1 ano)
-46.24%
País
BE
Negociar Celyad Oncology S.A. (CYAD)
Categoria
Healthcare
Histórico de preços das ações de Celyad Oncology S.A. (CYAD)
Preço de fecho mais alto: $0.59 em 2023-05-01
Preço de fecho mais baixo: $53.79 em 2015-06-01
Preço de fecho mais baixo: $53.79 em 2015-06-01
Histórico de preços das ações da Celyad Oncology S.A. de 2015 a 2026
Desempenho anual do preço das ações
| Ano | Desempenho |
|---|---|
| 2023 | -32.17% |
| 2022 | -78.99% |
| 2021 | -49.41% |
| 2020 | -23.42% |
| 2019 | -46.78% |
| 2018 | -48.41% |
| 2017 | 110.39% |
| 2016 | -62.32% |
| 2015 | 0.00% |
Preço das ações de empresas similares ou concorrentes
| Empresa | Preço da ação | Variação 1a% | País |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $758.70 | 7.84% |
CH
|
